These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 34355511)

  • 1. Prospective association of serum adipocyte fatty acid-binding protein with heart failure hospitalization in diabetes.
    Lee CH; Kan AKC; Lui DTW; Fong CHY; Chan DSH; Yuen MMA; Chow WS; Woo YC; Xu A; Lam KSL
    ESC Heart Fail; 2021 Oct; 8(5):3964-3974. PubMed ID: 34355511
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Prospective associations of circulating adipocyte fatty acid-binding protein levels with risks of renal outcomes and mortality in type 2 diabetes.
    Lee CH; Cheung CYY; Woo YC; Lui DTW; Yuen MMA; Fong CHY; Chow WS; Xu A; Lam KSL
    Diabetologia; 2019 Jan; 62(1):169-177. PubMed ID: 30267180
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Association between adipocyte fatty acid-binding protein with left ventricular remodelling and diastolic function in type 2 diabetes: a prospective echocardiography study.
    Wu MZ; Lee CH; Chen Y; Yu SY; Yu YJ; Ren QW; Fong HC; Wong PF; Tse HF; Lam SK; Yiu KH
    Cardiovasc Diabetol; 2020 Nov; 19(1):197. PubMed ID: 33234149
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Circulating AFABP, FGF21, and PEDF Levels as Prognostic Biomarkers of Sight-threatening Diabetic Retinopathy.
    Lee CH; Lui DT; Cheung CY; Fong CH; Yuen MM; Woo YC; Chow WS; Wong IY; Xu A; Lam KS
    J Clin Endocrinol Metab; 2023 Aug; 108(9):e799-e806. PubMed ID: 36856742
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prevention of heart failure events with sodium-glucose co-transporter 2 inhibitors across a spectrum of cardio-renal-metabolic risk.
    Bhatia K; Jain V; Gupta K; Bansal A; Fox A; Qamar A; Damman K; Vaduganathan M
    Eur J Heart Fail; 2021 Jun; 23(6):1002-1008. PubMed ID: 33609071
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Circulating Adipocyte Fatty Acid-Binding Protein Concentrations Predict Multiple Mortality Outcomes among Men and Women with Diabetes.
    Lee CH; Cheung CYY; Woo YC; Lui DTW; Yuen MMA; Fong CHY; Chow WS; Xu A; Lam KSL
    Clin Chem; 2018 Oct; 64(10):1496-1504. PubMed ID: 30021923
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical outcomes with the use of sodium-glucose cotransporter-2 inhibitors in patients with atrial fibrillation and type 2 diabetes mellitus: a multi-centre, real-world cohort study.
    Jang J; Park S; Kim S; Kim SH; Oh YS; Sa YK; Hwang Y; Jang SW; Ihm SH; Choi Y
    Eur J Prev Cardiol; 2024 Feb; 31(3):320-329. PubMed ID: 37798123
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective associations of circulating thrombospondin-2 level with heart failure hospitalization, left ventricular remodeling and diastolic function in type 2 diabetes.
    Lee CH; Wu MZ; Lui D; Fong C; Ren QW; Yu SY; Yuen M; Chow WS; Huang JY; Xu A; Yiu KH; Lam K
    Cardiovasc Diabetol; 2022 Nov; 21(1):231. PubMed ID: 36335340
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Use of sodium-glucose co-transporter 2 inhibitors in patients with heart failure and type 2 diabetes mellitus: data from the Swedish Heart Failure Registry.
    Becher PM; Schrage B; Ferrannini G; Benson L; Butler J; Carrero JJ; Cosentino F; Dahlström U; Mellbin L; Rosano GMC; Sinagra G; Stolfo D; Lund LH; Savarese G
    Eur J Heart Fail; 2021 Jun; 23(6):1012-1022. PubMed ID: 33599357
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Circulating branched-chain amino acids and incident heart failure in type 2 diabetes: The Hong Kong Diabetes Register.
    Lim LL; Lau ESH; Fung E; Lee HM; Ma RCW; Tam CHT; Wong WKK; Ng ACW; Chow E; Luk AOY; Jenkins A; Chan JCN; Kong APS
    Diabetes Metab Res Rev; 2020 Mar; 36(3):e3253. PubMed ID: 31957226
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Serum levels of adipocyte fatty acid-binding protein (AFABP) are increased in chronic haemodialysis (CD).
    Sommer G; Ziegelmeier M; Bachmann A; Kralisch S; Lossner U; Kratzsch J; Blüher M; Stumvoll M; Fasshauer M
    Clin Endocrinol (Oxf); 2008 Dec; 69(6):901-5. PubMed ID: 18419784
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Elevated circulating level of β-aminoisobutyric acid (BAIBA) in heart failure patients with type 2 diabetes receiving sodium-glucose cotransporter 2 inhibitors.
    Katano S; Yano T; Kouzu H; Nagaoka R; Numazawa R; Yamano K; Fujisawa Y; Ohori K; Nagano N; Fujito T; Nishikawa R; Ohwada W; Katayose M; Sato T; Kuno A; Furuhashi M
    Cardiovasc Diabetol; 2022 Dec; 21(1):285. PubMed ID: 36539818
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in serum adipocyte fatty acid-binding protein in women with gestational diabetes mellitus and normal pregnant women during mid- and late pregnancy.
    Zhang Y; Zhang HH; Lu JH; Zheng SY; Long T; Li YT; Wu WZ; Wang F
    J Diabetes Investig; 2016 Sep; 7(5):797-804. PubMed ID: 27181269
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lower risk of hospitalization for heart failure, kidney disease and death with sodium-glucose co-transporter-2 inhibitors compared with dipeptidyl peptidase-4 inhibitors in type 2 diabetes regardless of prior cardiovascular or kidney disease: A retrospective cohort study in UK primary care.
    Idris I; Zhang R; Mamza JB; Ford M; Morris T; Banerjee A; Khunti K
    Diabetes Obes Metab; 2021 Oct; 23(10):2207-2214. PubMed ID: 33973690
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Association between Markers of Fibrosis and Heart Failure Incidence in Patients with Type 2 Diabetes Mellitus.
    Lebedev DA; Lyasnikova EA; Vasilyeva EY; Likhonosov NP; Sitnikova MY; Babenko AY
    J Diabetes Res; 2021; 2021():9589185. PubMed ID: 34778465
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Impact of the initial decline in estimated glomerular filtration rate on the risk of new-onset atrial fibrillation and adverse cardiovascular and renal events in patients with type 2 diabetes treated with sodium-glucose co-transporter-2 inhibitors.
    Chan YH; Chen SW; Chao TF; Kao YW; Huang CY; Chu PH
    Diabetes Obes Metab; 2021 Sep; 23(9):2077-2089. PubMed ID: 34047459
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Association Between Serum Levels of Adipocyte Fatty Acid-binding Protein and Free Thyroxine.
    Tseng FY; Chen PL; Chen YT; Chi YC; Shih SR; Wang CY; Chen CL; Yang WS
    Medicine (Baltimore); 2015 Oct; 94(41):e1798. PubMed ID: 26469926
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting incident heart failure among patients with type 2 diabetes mellitus: The DM-CURE risk score.
    Lin Y; Shao H; Shi L; Anderson AH; Fonseca V
    Diabetes Obes Metab; 2022 Nov; 24(11):2203-2211. PubMed ID: 35801340
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Effect of Canagliflozin on Heart Failure Hospitalization in Diabetes According to Baseline Heart Failure Risk.
    Khan MS; Segar MW; Usman MS; Patel KV; Van Spall HGC; DeVore AD; Vaduganathan M; Lam CSP; Zannad F; Verma S; Butler J; Tang WHW; Pandey A
    JACC Heart Fail; 2023 Jul; 11(7):825-835. PubMed ID: 37227388
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Usefulness of Sodium-Glucose Cotransporter 2 Inhibitors for Primary Prevention of Heart Failure in Patients With Type 2 Diabetes Mellitus.
    Arbel R; Aboalhasan E; Hammerman A; Azuri J
    Am J Cardiol; 2021 Jul; 150():65-68. PubMed ID: 34001339
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.